Pharmaceuticals, Biotechnology and Life Sciences
Improved the Median Time to Disease Progression (37.2 months) vs. Bevacizumab Alone (17.7 months) Following Response to Platinum-Based Chemotherapy with…
BERLIN–(BUSINESS WIRE)–Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) a biotechnology company focused on improving cancer treatments by targeting…
RedHill Biopharma bagged approval from USFDA for its Investigational New Drug (IND) application for a Phase 2a clinical study to test its investigational drug, opaganib in patients with confirmed moderate-to-severe SARS-CoV-2 infection (the cause of COVID-19).
jCyte has entered a deal worth up to $252 million, including milestone payments of up to $190 million in potential milestones and royalties on net commercial sales for jCell.
First Quarter DEXTENZA® Net Product Revenue of $2.1 million, a 31% Sequential Increase Compared with Fourth Quarter of 2019
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended March 31, 2020, including revenues…
Schreiner MediPharm has developed a compact Booklet-Label for a needle protection system used in an international phase III clinical trial conducted by pharmaceutical corporation Sanofi.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner CANbridge Pharmaceuticals, Inc. has received marketing approval of NERLYNX® (neratinib) in mainland China from the National Medical Products Administration (NMPA) of China.
Certara is applying expertise in clinical pharmacology, innovation and collaboration to accelerate potential prophylaxis for COVID-19.
Bristol Myers Squibb has reported first quarter revenues of $10.8 Billion, an increase of 82%, on a pro forma basis, revenue increase of 13% or 8% excluding impact of COVID-19.